You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 9,320,811

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,320,811

Title:	Combination of anti-CTLA4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
Abstract:	Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders.
Inventor(s):	Jure-Kunkel; Maria (Plainsboro, NJ)
Assignee:	Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:	14/168,465
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,320,811
Patent Claims:	1. A method for the treatment of cancer, comprising the concurrent administration to a mammal in need thereof a synergistic, therapeutically effective amount of an anti-CTLA-4 antibody with 2'-deoxy-2',2'-difluorocytidine monohydrochloride (.beta.-isomer), or a pharmaceutically acceptable salt, solvate, or hydrate thereof. 2. The method according to claim 1, wherein the anti-CTLA-4 antibody is selected from the group consisting of: ipilimumab and tremelimumab. 3. The method according to claim 1, wherein said anti-CTLA-4 antibody is ipilimumab. 4. The method according to claim 1, wherein said cancer is a solid tumor. 5. The method according to claim 4, wherein said solid tumor is selected from the group consisting of: lung carcinoma, lung metastasis, and colon carcinoma. 6. The method according to claim 1, wherein said method is for the treatment of a tumor refractory to said monohydrochloride. 7. The method according to claim 1, wherein said monohydrochloride is administered essentially simultaneously with the administration of said anti-CTLA4 antibody. 8. The method according to claim 1, wherein said cancer treatment further comprises an anti-proliferative cytotoxic agent either alone or in combination with radiation therapy. 9. The method according to claim 8, wherein said anti-proliferative cytotoxic agent is cisplatin. 10. The method according to claim 8, wherein said anti-proliferative cytotoxic agent is paraplatin. 11. The method according to claim 1, wherein said monohydrochloride is administered at a dose of about 200 mg. 12. The method according to claim 1, wherein said monohydrochloride is administered at a dose of about 1 g. 13. The method according to claim 1, wherein said monohydrochloride is administered via IV infusion. 14. The method according to claim 1, wherein said anti-CTLA4 antibody is administered about every three weeks. 15. The method according to claim 4, wherein said solid tumor is lung carcinoma. 16. The method according to claim 4, wherein said solid tumor is lung metastasis. 17. The method according to claim 4, wherein said solid tumor is colon carcinoma.

Details for Patent 9,320,811

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bristol-myers Squibb Company	YERVOY	ipilimumab	Injection	125377	03/25/2011	⤷ Try a Trial	2028-08-01
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.